SYRE Stock Forecast 2025-2026
Distance to SYRE Price Targets
SYRE Price Momentum
10 Quality Stocks Worth Considering Now
Researching Spyre (SYRE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SYRE and similar high-potential opportunities.
Latest SYRE Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, SYRE has a bullish consensus with a median price target of $65.00 (ranging from $27.00 to $71.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $18.16, the median forecast implies a 257.9% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Alex Thompson at Stifel, suggesting a 48.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYRE Analyst Ratings
SYRE Price Target Range
Latest SYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 11, 2024 | Jones Trading | Debanjana Chatterjee | Hold | Initiates | $0.00 |
| Nov 13, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $65.00 |
| Oct 25, 2024 | Guggenheim | Yatin Suneja | Buy | Maintains | $65.00 |
| Sep 4, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $45.00 |
| Jul 16, 2024 | Evercore ISI Group | Umer Raffat | Outperform | Initiates | $0.00 |
| May 13, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $40.00 |
| May 10, 2024 | BTIG | Julian Harrison | Buy | Maintains | $40.00 |
| May 2, 2024 | Baird | Colleen Kusy | Outperform | Initiates | $50.00 |
| Mar 26, 2024 | Stifel | Alex Thompson | Buy | Reiterates | $54.00 |
| Mar 1, 2024 | Wells Fargo | Yanan Zhu | Overweight | Upgrade | $35.00 |
| Dec 20, 2023 | BTIG | Julian Harrison | Buy | Initiates | $32.00 |
| Dec 18, 2023 | Stifel | Alex Thompson | Buy | Maintains | $27.00 |
| Dec 11, 2023 | Jefferies | Akash Tewari | Buy | Initiates | $31.00 |
| Dec 11, 2023 | Guggenheim | Buy | Initiates | $44.00 | |
| Nov 29, 2023 | TD Cowen | Tyler Van Buren | Outperform | Initiates | $0.00 |
Spyre Therapeutics Inc. (SYRE) Competitors
The following stocks are similar to Spyre based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Spyre Therapeutics Inc. (SYRE) Financial Data
Spyre Therapeutics Inc. has a market capitalization of $1.09B with a P/E ratio of 1.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -59.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Spyre Therapeutics Inc. (SYRE) Business Model
About Spyre Therapeutics Inc.
Develops therapies for autoimmune and inflammatory diseases.
Spyre Therapeutics generates revenue through the research and development of innovative biopharmaceutical therapies. By focusing on drug discovery, the company aims to bring novel medicines to market, addressing the root causes of autoimmune and inflammatory disorders.
The company operates within the biotechnology sector and has a diverse pipeline of biologic and small molecule drugs. Spyre Therapeutics is positioned as a potential growth driver in the biotech industry, appealing to investors interested in impactful healthcare solutions and advancements in treating unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Dr. Cameron Turtle DPHIL, Ph.D.
Country
United States
IPO Year
2016
Website
www.spyre.comSpyre Therapeutics Inc. (SYRE) Latest News & Analysis
Spyre Therapeutics approved stock options for 132,200 shares to five non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.
The granting of stock options to employees can indicate confidence in the companyโs future, potentially boosting morale and aligning employee interests with shareholders, which may influence stock performance.
Spyre Therapeutics focuses on monoclonal antibodies for inflammatory bowel disease, has $603.1 million in cash, and aims for improved efficacy in ulcerative colitis with combination therapies.
Spyre Therapeutics' strong cash position and innovative therapies in inflammatory bowel disease could lead to significant market opportunities, enhancing its valuation and growth potential.
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
27 days agoSpyre Therapeutics reported positive Phase 1 trial data for SPY001 and raised $230 million in a public offering. Phase 2 trials for SPY001, SPY002, and SPY003 are set for mid-2025, with cash reserves of $603 million.
Positive trial results and a strong balance sheet position Spyre Therapeutics for potential growth. Upcoming milestones in drug development could drive stock performance and investor interest.
Spyre Therapeutics (NASDAQ: SYRE) will participate in the TD Cowen Healthcare Conference on March 4 and the Jefferies Biotech Summit on March 11, 2025, offering investor meetings and webcasts.
Spyre Therapeutics' participation in major investor conferences signals potential interest and visibility in the biotech sector, possibly impacting investor sentiment and stock performance.
Spyre Therapeutics (NASDAQ: SYRE) presented at the ECCO Congress on the efficacy of combined ฮฑ4ฮฒ7 integrin and TL1A cytokine inhibition for treating IBD, showing superior results in mouse models.
Spyre Therapeutics' positive data on its dual therapy for IBD could enhance its market position and attract investor interest, potentially boosting stock value and future funding opportunities.
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
1 month agoSpyre Therapeutics (SYRE) has a consensus price target indicating a 158.9% upside. Upward revisions in earnings estimates may suggest potential short-term gains.
A 158.9% upside potential suggests significant growth for Spyre Therapeutics (SYRE), while rising earnings estimates indicate positive momentum, potentially driving stock prices higher.
Frequently Asked Questions About SYRE Stock
What is Spyre Therapeutics Inc.'s (SYRE) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Spyre Therapeutics Inc. (SYRE) has a median price target of $65.00. The highest price target is $71.00 and the lowest is $27.00.
Is SYRE stock a good investment in 2025?
According to current analyst ratings, SYRE has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYRE stock?
Wall Street analysts predict SYRE stock could reach $65.00 in the next 12 months. This represents a 257.9% increase from the current price of $18.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Spyre Therapeutics Inc.'s business model?
Spyre Therapeutics generates revenue through the research and development of innovative biopharmaceutical therapies. By focusing on drug discovery, the company aims to bring novel medicines to market, addressing the root causes of autoimmune and inflammatory disorders.
What is the highest forecasted price for SYRE Spyre Therapeutics Inc.?
The highest price target for SYRE is $71.00 from at , which represents a 291.0% increase from the current price of $18.16.
What is the lowest forecasted price for SYRE Spyre Therapeutics Inc.?
The lowest price target for SYRE is $27.00 from Alex Thompson at Stifel, which represents a 48.7% increase from the current price of $18.16.
What is the overall SYRE consensus from analysts for Spyre Therapeutics Inc.?
The overall analyst consensus for SYRE is bullish. Out of 11 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $65.00.
How accurate are SYRE stock price projections?
Stock price projections, including those for Spyre Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
